MAPT and Alzheimer disease: However, at the later stages of disease where cognitive decline has become apparent, [18-F]AV1451 PET tau has proven to be a significantly better diagnostic tool of AD than CSF measures, hippocampal atrophy, or temporal cortices thickness (50).